Deals

Financial terms of the deal were undisclosed. The move is set to enhance Kindeva’s drug-delivery capabilities by adding a new platform to its portfolio. Kindeva CEO Milton Boyer

This development is part of Galapagos’ strategy to transform into a new biotechnology enterprise with a robust research and development pipeline for treating disease immunology and oncology fields.

In October this year, Lilly signed a definitive agreement for POINT Biopharma acquisition. POINT Biopharma focuses on developing radioligand treatments for cancer and has a pipeline of such

The deal value comprised an upfront cash payment of $1.75bn, apart from further milestone payments in the future. The parties entered an agreement in this regard in June 2023.

Lilly signed the definitive agreement to acquire Versanis Bio in July this year. At the time of the deal announcement, its terms specified that shareholders of Versanis were

Bellus focuses on improving the lives of individuals suffering from persistent cough. In April this year, GSK reached an agreement for the acquisition of Bellus Health. The takeover comprises the

Comac founder and CEO Dr Milen Vrabevski and its other shareholders will retain a significant minority stake. The companies have not disclosed the financial terms of the deal.

The definitive agreement between the companies was initially signed in January this year. The total deal value at close is nearly $1.2bn in upfront consideration and contingent value

The independent bid committee of Sensidose has recommended the cash offer. At present, the shares of Sensidose are listed on Spotlight Stock Market in Sweden. Sensidose is involved